Determinants of variable response to simvastatin treatment: The role of common variants of SCAP, SREBF-1a and SREBF-2 genes

Pharmacogenomics Journal

Volumn 5, Issue 6, 2005, Pages 359-364

  Fiegenbaum, M ^a   Silveira, F R ^a   Van der Sand, C R ^b   Van der Sand, L C ^b   Ferreira, M E W ^b   Pires, R C ^b   Hutz, Mara H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Centro de Diagnóstico Cardiológico   (Brazil)

Author keywords

Pharmacogenetics; SCAP SREBF pathway; Simvastatin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; STEROL REGULATORY ELEMENT BINDING PROTEIN CLEAVAGE ACTIVATING PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; SIGNAL PEPTIDE; SREBF1 PROTEIN, HUMAN; SREBF2 PROTEIN, HUMAN; SREBP CLEAVAGE ACTIVATING PROTEIN; SREBP CLEAVAGE-ACTIVATING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ADULT; AGED; ALLELE; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT; BLOOD; GENETICS; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIGLYCERIDES;

EID: 33644677542     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500334     Document Type: Article

References (29)

1. Pignone M, Phillips C, Multow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomised trials. BMJ 2001; 321: 1-5.
2. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10.
3. Gotto AM. Emerging perspectives on lipid management: International approaches and global challenges. Am J Cardiol 2001; 88: 876-881.
4. Maitland-van der Zee AH, Klungel OH, Stricker BHC, Verschuren WMM, Kastelein JJP, Leufkens HGM et al. Genetic polymorphisms: Importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002; 163: 213-222.
5. Hoffman MM, Winkelmann BR, Wieland H, Marz W. The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs. Pharmacogenomics 2001; 2: 1-11.
6. Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F. SREBP transcription factors: Master regulators of lipid homeostasis. Biochimie 2004; 86: 839-848.
7. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA 1999; 96: 11041-11048.
8. Edwards PA, Tabor D, Kast HR, Venkasteswaran A. Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta 2000; 1529: 103-113.
9. Gimpl G, Burger K, Fahrenholz F. A closer look at the cholesterol sensor. Trends Biochem Sci 2002; 27: 596-599.
10. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131.
11. Nakajima T, Hamakubo T, Kodama T, Inazawa J, Emi M. Genomic structure and chromosomal mapping of the human sterol regulatory element binding protein (SREBP) cleavage-activating protein (SCAP) gene. J Hum Genet 1999; 44: 402-407.
12. Hua X, Nohturfft A, Goldstein JL, Brown MS. Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein. Cell 1996; 10: 1096-1107.
13. Salek L, Lutucuta S, Ballantyne CM, Gotto Jr AM, Marian AJ. Effects of SREBF-1 a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med 2002; 80: 737-744.
14. Fan YM, Laaksonen R, Janatuinen T, Vesalainen R, Nuutila P, Knuuti J et al. Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men. Clin Genet 2001; 60: 319-321.
15. Beiard SL. HMG-Coa reductase inhibitors: Assessing differences in drug interactions and safety profiles. Am J Pharm Assoc 2000; 40: 637-644.
16. Chong PH, Seeger JD, Franklin C. Cinically relevant differences between the statins: Implications for therapeutic selection. Am J Med 2001; 111: 390-400.
17. Igel M, Sudhop T, vonBergmann K. Metabolism and drug interaction of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57: 357-367.
18. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 2003; 100: 177-182.
19. Zembrzusky VM, Callegari-Jacques SM, Hutz MH. Utilização de marcadores autossomicos para o controle de estratificação populacional em estudos de associação. Anais do 50° Congresso Brasileiro de Genética 2004. Florianopolis: Brazil, p 503.
20. Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res 2001; 40: 439-452.
21. Yang WS, Deeb SS. Sp1 and Sp3 transactivate the human lipoprotein lipase gene promoter through binding to a CT element: Synergy with the sterol regulatory element binding protein and reduced transactivation of a naturally occurring promoter variant. J Lipid Res 1998; 39: 2054-2064.
22. Botma GJ, van Deursen D, Vieira D, van Hoek M, Jansen H, Verhoeven AJM. Sterol-regulatory-element binding protein inhibits upstream stimulatory factor-stimulated hepatic lipase gene expression. Atherosclerosis 2005; 179: 61-67.
23. Salzano FM, Freire-Mafia N. Problems in Human Biology. A Study of Brazilian Populations. Wayne State University Press: Detroit, 1970.
24. Friedewald NT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without using the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
25. Lahiri DK, Nurnberger JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acid Res 1991; 19: 5444.
26. Iwaki K, Nakajima T, Ota N, Emi M. A common Ile796Val polymorphism of the human SREBP cleavage-activating protein (SOAP) gene. J Hum Genet 1999; 44: 421-422.
27. Védie B, Jeunemaitre X, Mégnien JL, Atger V, Simon A, Moatti N. A new DNA polymorphism in the 5′ untranslated region of the human SREBP- 1a is related to development of atherosclerosis in high cardiovascular risk population. Atherosclerosis 2001; 154: 589-597.
28. Miserez AR, Muller PY, Barella L, Barella S, Staehelin B, Leitersdorf E et al. Sterol-regulatory element-binding protein (SREBP-2) contributes to polygenic hypercholesterolemia. Atherosclerosis 2002; 164: 15-26.
29. Dupont WD, Plummer WD. PS power and sample size program available for free on the Internet. Control Clin Trials 1997; 18: 274.